Interviews

Suzette Kox, MPharm, Secretary General of the International Generic and Biosimilar Medicines Association (IGBA), discusses challenges faced jointly by the US and EU biosimilars markets.

Gillian Woollett, MA, DPhil, senior vice president, Avalere Health, discusses how confirming "sufficient likeness" in biosimilar development can and should replace the current "totality of the evidence” approach to biosimilar development.